A Phase 1, Double-Blind, Randomized, Single Ascending Dose Study of the Safety and Tolerability of MEDI-570 in Systemic Lupus Erythematosus.
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2014
At a glance
- Drugs MEDI 570 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors MedImmune
- 06 Sep 2012 Planned End Date changed from 1 Nov 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 01 Sep 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 30 Jan 2012 Planned number of patients changed from 50 to 46 as reported by ClinicalTrials.gov.